These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Update on research and development pipeline: tuberculosis vaccines. Beresford B; Sadoff JC Clin Infect Dis; 2010 May; 50 Suppl 3():S178-83. PubMed ID: 20397946 [TBL] [Abstract][Full Text] [Related]
3. Antituberculous vaccine development: a perspective for the endemic world. Verma I; Grover A Expert Rev Vaccines; 2009 Nov; 8(11):1547-53. PubMed ID: 19863247 [TBL] [Abstract][Full Text] [Related]
4. Tuberculosis vaccines: a strategic blueprint for the next decade. Brennan MJ; Thole J Tuberculosis (Edinb); 2012 Mar; 92 Suppl 1():S6-13. PubMed ID: 22441160 [No Abstract] [Full Text] [Related]
5. A good vaccine is hard to find: nonprofit biotechs tackle tuberculosis. Wolfson W Chem Biol; 2008 Oct; 15(10):997-8. PubMed ID: 18940659 [No Abstract] [Full Text] [Related]
6. Questions for biotechs. Bachmann M Hum Vaccin; 2010 Jul; 6(7):527. PubMed ID: 20622523 [No Abstract] [Full Text] [Related]
8. The second Geneva Consensus: Recommendations for novel live TB vaccines. Walker KB; Brennan MJ; Ho MM; Eskola J; Thiry G; Sadoff J; Dobbelaer R; Grode L; Liu MA; Fruth U; Lambert PH Vaccine; 2010 Mar; 28(11):2259-70. PubMed ID: 20074686 [TBL] [Abstract][Full Text] [Related]
9. The development and impact of tuberculosis vaccines. Young D; Dye C Cell; 2006 Feb; 124(4):683-7. PubMed ID: 16497578 [TBL] [Abstract][Full Text] [Related]
10. Novel tuberculosis vaccines on the horizon. Parida SK; Kaufmann SH Curr Opin Immunol; 2010 Jun; 22(3):374-84. PubMed ID: 20471231 [TBL] [Abstract][Full Text] [Related]
11. Letter from the editor. Ellis RW; Riedmann EM Hum Vaccin Immunother; 2012 Mar; 8(3):281. PubMed ID: 22418878 [No Abstract] [Full Text] [Related]
12. Deal watch: Trends in platform technology deal-making. Walker J; Jacob J Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395 [No Abstract] [Full Text] [Related]
13. Transforming biomedical research to develop effective TB vaccines: the next ten years. Sizemore CF; Fauci AS Tuberculosis (Edinb); 2012 Mar; 92 Suppl 1():S2-3. PubMed ID: 22441154 [No Abstract] [Full Text] [Related]
14. Development of new tuberculosis vaccines: a global perspective on regulatory issues. Brennan MJ; Fruth U; Milstien J; Tiernan R; de Andrade Nishioka S; Chocarro L; PLoS Med; 2007 Aug; 4(8):e252. PubMed ID: 17683198 [TBL] [Abstract][Full Text] [Related]
16. Planning in the context of a virtuous cycle for tuberculosis vaccine development. Small PM Tuberculosis (Edinb); 2012 Mar; 92 Suppl 1():S4-5. PubMed ID: 22441159 [No Abstract] [Full Text] [Related]
18. [Research and development of vaccines against tuberculosis]. Kobayashi K; Sugawara I Kekkaku; 2008 Sep; 83(9):635-40. PubMed ID: 18979998 [No Abstract] [Full Text] [Related]
19. Real vaccines in the real world: tuberculosis vaccines move south. Dockrell HM Expert Rev Vaccines; 2008 Aug; 7(6):703-7. PubMed ID: 18665767 [No Abstract] [Full Text] [Related]
20. [The study on the Mycobacterium tuberculosis antigen 85 complex and its application in the future]. Lu Y; Zhu LZ; Duan LS Zhonghua Jie He He Hu Xi Za Zhi; 2003 Aug; 26(8):481-4. PubMed ID: 14627025 [No Abstract] [Full Text] [Related] [Next] [New Search]